New data provide guidance to personalise treatment in recurrent and metastatic salivary gland cancer
Two studies report the results about the use of trastuzumab deruxtecan and androgen deprivation therapy for patients with this rare cancer
Eftilagimod alpha plus pembrolizumab shows promise in HNSCC with negative PD-1 expression
In the Cohort B of the TACTI-003 study, the combination therapy led to clinically meaningful response rates in patients with recurrent or metastatic disease
Preventive immunotherapy shows some activity in pre-cancer oral lesions
A phase II trial opens up discussions on how to define success of chemoprevention studies
Targeted therapy shows early promise in EBV-positive nasopharyngeal carcinoma
In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy
Three decades of progress in nasopharyngeal cancer
Tailored management for high-risk locoregional disease, together with more effective immunotherapy combinations are key areas of exploration in nasopharyngeal cancer, according to 2023 ESMO Lifetime Achievement awardee Prof. Anthony Chan
Is combining radiotherapy and immunotherapy a viable treatment option?
Conflicting clinical results on the benefits of combined radiotherapy and immunotherapy may derive from differences in treatment sequencing
Nivolumab shows encouraging efficacy in high-risk patients with precancerous oral lesions
Results of a small phase II trial may open up a new option for some patients with leukoplakia, but toxicity of immunotherapy is high and questions remain about its utility in clinical practice
A new immunotherapy-based combination is promising in nasopharyngeal cancer
Tislelizumab in combination with gemcitabine and cisplatin prolonged PFS compared with chemotherapy alone in the RATIONALE 309 study
Genetics and availability of treatments influence the management of head and neck cancer in Asia
The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines is presented at the ESMO Asia Virtual Oncology Week 2021
GORTEC-REACH study results fail to change the current standard of care for locally advanced SCCHN
Adding an immune checkpoint inhibitor to cetuximab plus radiotherapy does not improve outcomes versus standard of care in locally advanced squamous cell carcinoma of the head and neck